Vermillion Takes Control: Dx Firm Launches Its Own Lab To Market Ovarian Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
Not happy with market penetration since its FDA-cleared OVA1 ovarian cancer molecular assay launched exclusively via Quest Diagnostics in 2009, Vermillion has launched ASPiRA Labs to more directly connect with OB-GYN customers.